Am J Psychiatry. 1987 Oct;144(10):1253-62. doi: 10.1176/ajp.144.10.1253.
The dexamethasone suppression test (DST) has had unprecedented evaluation among biological tests proposed for clinical use in psychiatry. It is hypothesized to reflect pathophysiologic changes at the CNS level. The sensitivity of the DST (rate of a positive outcome, or nonsuppression of cortisol) in major depression is modest (about 40%-50%) but is higher (about 60%-70%) in very severe, especially psychotic, affective disorders, including major depression with psychotic as well as melancholic features, mania, and schizoaffective disorder. The specificity (true negative outcome) of the DST in normal control subjects is above 90%, but it varies from less than 70% to more than 90% in psychiatric conditions that often need to be separated from major affective disorders. In dementia the specificity is even lower. In addition, a number of medical conditions, including severe weight loss and use of alcohol and certain other drugs (barbiturates, anticonvulsants, and others), can produce false positive results. Positive initial DST status in major depression does not add significantly to the likelihood of antidepressant response, and a negative test is not an indication for withholding antidepressant treatment. Some recent data suggest that DST-positive depressions (cortisol nonsuppression) are less likely than DST-negative cases (cortisol suppression) to respond to a placebo. If this is confirmed, it would increase the real magnitude of the difference in treatment response between DST-positive and DST-negative depressed patients. Failure to convert to normal suppression of cortisol with apparent recovery from depression suggests an increased risk for relapse into depression or suicidal behavior. Although the clinical utility of the DST as currently understood is limited, in certain specific situations its thoughtful use may aid clinical decision making. The association of an abnormal test result with major affective disorders encourages continued research on the DST.
地塞米松抑制试验(DST)在为精神病学临床应用所提出的生物学检测中得到了前所未有的评估。据推测,它能反映中枢神经系统水平的病理生理变化。DST在重度抑郁症中的敏感性(阳性结果率,即皮质醇未被抑制)适中(约40%-50%),但在非常严重的,尤其是伴有精神病性症状的情感障碍中更高(约60%-70%),这些情感障碍包括伴有精神病性及抑郁性特征的重度抑郁症、躁狂症和分裂情感性障碍。DST在正常对照受试者中的特异性(真阴性结果)高于90%,但在通常需要与重度情感障碍相鉴别的精神疾病中,其特异性从低于70%到高于90%不等。在痴呆症中,特异性甚至更低。此外,一些医学状况,包括严重体重减轻以及使用酒精和某些其他药物(巴比妥类药物、抗惊厥药等),可能会产生假阳性结果。重度抑郁症患者DST初始状态为阳性,并不会显著增加对抗抑郁药产生反应的可能性,而检测结果为阴性也不是停用抗抑郁药治疗的指征。一些近期数据表明,DST阳性的抑郁症(皮质醇未被抑制)比DST阴性的病例(皮质醇被抑制)对安慰剂反应的可能性更小。如果这一点得到证实,将会加大DST阳性和DST阴性抑郁症患者在治疗反应上的实际差异程度。抑郁症明显缓解但未能恢复到正常的皮质醇抑制状态,提示复发为抑郁症或出现自杀行为的风险增加。尽管目前对DST临床效用的理解有限,但在某些特定情况下,谨慎使用它可能有助于临床决策。检测结果异常与重度情感障碍之间的关联促使人们继续对DST展开研究。